Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Innoviva, Inc.

Innoviva to Participate in the UBS Global Healthcare Conference
From Innoviva, Inc.
Via Business Wire
Tickers INVA
Innoviva Reports Third Quarter 2024 Financial Results; Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
Tickers INVA
Innoviva to Participate in Upcoming Investor Conferences
From Innoviva, Inc.
Via Business Wire
Tickers INVA
Innoviva Reports Second Quarter 2024 Financial Results; Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
Tickers INVA
Innoviva to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
From Innoviva, Inc.
Via Business Wire
Tickers INVA
Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
Tickers INVA
Innoviva to Participate in the BofA Securities Health Care Conference
From Innoviva, Inc.
Via Business Wire
Tickers INVA
Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
Tickers INVA
Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
Tickers INVA
Innoviva Specialty Therapeutics Presents New Data on its Critical Care Antibiotic Therapy Portfolio at Infectious Disease Week (IDWeek) 2023
From Innoviva, Inc.
Via Business Wire
Innoviva to Participate in the Cantor Global Healthcare Conference
From Innoviva, Inc.
Via Business Wire
Tickers INVA
XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in Adults
From Innoviva, Inc.
Via Business Wire
Tickers INVA
Innoviva Appoints Stephen Basso as Chief Financial Officer
From Innoviva, Inc.
Via Business Wire
Tickers INVA
Innoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
Tickers INVA
Innoviva to Participate in the Goldman Sachs Annual Global Healthcare Conference
From Innoviva, Inc.
Via Business Wire
Tickers INVA
Innoviva Specialty Therapeutics Announces FDA Approval for XACDURO® (sulbactam for injection; durlobactam for injection), Co-packaged for Intravenous Use
From Innoviva, Inc.
Via Business Wire
Tickers INVA
Results from Pivotal Phase 3 ATTACK Trial of Investigational Sulbactam-Durlobactam for Treatment of Serious Infections Caused by Acinetobacter Published in The Lancet Infectious Diseases
From Innoviva, Inc.
Via Business Wire
Tickers INVA
Innoviva Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
Tickers INVA
Innoviva Announces Retirement of Board Chairman
From Innoviva, Inc.
Via Business Wire
Tickers INVA
Sulbactam-Durlobactam Unanimously Recommended for Approval by FDA Advisory Committee
From Innoviva, Inc.
Via Business Wire
Tickers INVA
Innoviva Stock Trading Halted Today
From Innoviva, Inc.
Via Business Wire
Tickers INVA
Innoviva Announces FDA Advisory Committee Meeting to Review Sulbactam-Durlobactam (SUL-DUR), an Investigational Targeted Antibiotic
From Innoviva, Inc.
Via Business Wire
Tickers INVA
Innoviva Reports Fourth Quarter 2022 Financial Results and Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
Tickers INVA
Innoviva Announces FDA Acceptance and Priority Review of New Drug Application for Sulbactam-Durlobactam (SUL-DUR)
From Innoviva, Inc.
Via Business Wire
Tickers INVA
Innoviva Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
Tickers INVA
Innoviva to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
From Innoviva, Inc.
Via Business Wire
Tickers INVA
Innoviva Completes Acquisition of La Jolla Pharmaceutical
From Innoviva, Inc.
Via Business Wire
Tickers INVA LJPC
Innoviva Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
Tickers INVA
Innoviva Sells 15% Economic Stake in Theravance Respiratory Company to Royalty Pharma for approximately $282 million plus full ownership of existing equity investments and the potential for $50 million milestone payment
From Innoviva, Inc.
Via Business Wire
Tickers INVA
Innoviva Completes Acquisition of Entasis Therapeutics
From Innoviva, Inc.
Via Business Wire
Tickers INVA
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.